Guidelines, presents no significant risk to health or the 
environment, and presents no significant risk of (i) adverse 
impacts on the civil liberties or on the social or economic 
status of those persons who may be the subject of proposed 
actions involving gene therapy, (ii) creating undue ethical 
or philosophical dilemmas or problems for such persons, and 
(iii) encouraging unsound, undesirable or frivolous human 
eugenics practices by either public or private institutions 
or individual practitioners. The term "significant risk" 
herein includes adverse implications for the interest to be 
protected . 
Amend Section IV-C-l-b-(l) by adding "and the HEAC " after 
"the RAC" wherever it appears in that provision. 
Amend Section IV-C-3-b-(l) by adding "and HEAC" after "RAC" 
where it appears in the text. In the note that follows the text, 
add "or a HEAC" before "meeting". 
Amend Section IV-C-3-b-(2) by adding "and HEAC" after "RAC" 
and change "meeting" to "meetings". 
Amend Sections IV-C-3-b-(3) and IV-C-3-d by adding "the 
HEAC" after "RAC". 
The reasons for these proposed revisions are set forth in 
the Petition to the Director accompanying these proposals. 
[462] 
Recombinant DNA Research, Volume 13 
